Drug Pipeline DevelopmentThe ProfoundBio acquisition provides Genmab with a late-stage asset, Rina-S, that could receive its first approval by 2027, potentially enhancing its product pipeline.
Financial Performance And RatingsAnalyst reiterates a Buy rating with a 12-month price target of $50 per share for the company's stock.
Regulatory MilestonesRina-S received Fast Track Designation from the FDA, with anticipation of additional data in the second half of the year.